Bloomberg Anywhere Remote Login Bloomberg Terminal Demo Request


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last €110.46 EUR
Change Today +0.212 / 0.19%
Volume 30.0
As of 1:37 PM 10/9/15 All times are local (Market data is delayed by at least 15 minutes).

thermo fisher scientific inc (TN8) Snapshot

Previous Close
Day High
Day Low
52 Week High
07/22/15 - €128.57
52 Week Low
10/15/14 - €84.20
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield

thermo fisher scientific inc (TN8) Details

Thermo Fisher Scientific Inc. provides analytical instruments, equipment, reagents and consumables, software, and services for research, manufacturing, analysis, discovery, and diagnostics worldwide. The company’s Life Sciences Solutions segment offers reagents, instruments, and consumables used in biological and medical research, discovery, and production of new drugs and vaccines, as well as diagnosis of diseases. This segment serves pharmaceutical, biotechnology, agricultural, clinical, academic, and government markets. Its Analytical Instruments segment provides instruments, consumables, software, and services for applications in the laboratory, on the production line, and in the field. It serves pharmaceutical, biotechnology, academic, government, environmental, and other research and industrial markets, as well as the clinical laboratory. The company’s Specialty Diagnostics segment offers liquid, ready-to-use and lyophilized immunodiagnostic reagent kits, calibrators, controls, and calibration verification fluids; blood-test systems to support the clinical diagnosis and monitoring of allergy, asthma, and autoimmune diseases; dehydrated and prepared culture media, collection and transport systems, instrumentation, and consumables; products for cancer diagnosis and medical research in histology, cytology, and hematology; and human leukocyte antigen typing and testing for the organ transplant market. This segment serves healthcare, clinical, pharmaceutical, industrial, and food safety laboratory customers. Its Laboratory Products and Services segment offers sample preparation and preservation equipment, cold storage equipment, centrifugation products, biological safety cabinets, temperature control products, water analysis instruments, and other laboratory equipment, as well as laboratory consumables, research and safety market solutions, and biopharma services. Thermo Fisher Scientific Inc. was founded in 1956 and is headquartered in Waltham, Massachusetts.

51,000 Employees
Last Reported Date: 03/5/15
Founded in 1956

thermo fisher scientific inc (TN8) Top Compensated Officers

Chief Executive Officer, President, Director,...
Total Annual Compensation: $1.3M
Executive Vice President and President of Lif...
Total Annual Compensation: $723.1K
Executive Vice President and President of Lab...
Total Annual Compensation: $716.2K
Senior Vice President and President of Analyt...
Total Annual Compensation: $568.1K
Chief Administrative Officer, Senior Vice Pre...
Total Annual Compensation: $674.0K
Compensation as of Fiscal Year 2014.

thermo fisher scientific inc (TN8) Key Developments

Thermo Fisher Scientific, Inc. Presents at Alliance for Regenerative Medicine Stem Cell Meeting on the Mesa, Oct-07-2015 09:15 AM

Thermo Fisher Scientific, Inc. Presents at Alliance for Regenerative Medicine Stem Cell Meeting on the Mesa, Oct-07-2015 09:15 AM. Venue: Estancia La Jolla Hotel & Spa, 9700 North Torrey Pines Road, La Jolla, CA 92037, United States. Speakers: Amy Butler, VP & General Manager, Cell Biology.

Thermo Fisher Scientific Inc. Launches New Serum Replacement for Immune Cell Culture

Thermo Fisher Scientific Inc. has launched a new serum replacement for immune cell culture, the GIBCO CTS Immune Cell SR. The GIBCO CTS Immune Cell SR can be used with many base media in less time, with lower costs and with greater consistency than traditional sera to support a wide range of immune cells, including CAR T cells. Human serum and FBS have been traditional supplements of immune cell cultures for both diagnostic purposes and clinical research cell production, but there are risks of short supply, lot variability and safety. The new CTS Immune Cell SR easily replaces human serum, easing the tissue culture of clinical research and diagnostic samples. The serum replacement can help boost the rapidly growing field of immune cell culture for research and therapeutic development. Reliable cell culture is absolutely essential to successful research and bioproduction applications, and that depends on a safe and reliable source of serum to supplement cell culture. However, as the use of cell culture for translational immune cell research and clinical development has risen, the supply of serum from human and fetal bovine sources has been steadily decreasing. The CTS Immune Cell SR provides the first replacement for human serum and FBS that can provide the same immune cell growth as previously used sera. The CTS Immune Cell SR is a defined formulation with no bovine or non-human animal-derived components at the primary component level. Thermo Fisher manufactures serum replacement at a FDA-registered site operating to ISO 13485 (medical devices) certification. The product can be used with other CTS Immunotherapy products such as OpTmizer; AIM-V; and cytokines, such as IL-2 and Dynabeads CD3/CD28 products, for a complete immune cell culture workflow. CTS Immune Cell SR is available in volumes suitable for research and can easily be scaled-up to meet future clinical and commercial demands. CTS Immune Cell SR is T cell-qualified, and it is classified as a FDA Class 1 in vitro diagnostic medical device. It can replace human serum, providing similar performance at similar concentrations. GIBCO serum replacement supports the expansion of CD3/CD28 bead-activated T cells and TILs, CD4, CD8, and CD62L, lentiviral transduction of T cells and functional CAR T cells in vivo, as demonstrated by James Riley, Ph.D at the University of Pennsylvania and presented during the corporate tutorial at the International Society of Cell Therapy meeting. Every lot is prequalified in a functional T cell assay. These innovations help reduce costs and time spent on human serum lot testing and offer a more secure and consistent cell culture experience.

Thermo Fisher Scientific Inc. Launches New Nano LC System and Columns for Proteomics Research

Thermo Fisher Scientific Inc. has launched new nano LC system and columns for proteomics research. Proteomics laboratories can benefit from a new nano LC system with dedicated columns as front-end for liquid chromatography mass spectrometry (LC-MS). The new Thermo Scientific EASY-nLC 1200 system with a pressure capacity of 1200 bar is designed to provide effortless separation performance and high-throughput capacity. The EASY-nLC 1200 was designed for robust and reliable operation at 1200 bar. New maintenance-free ceramic valves decrease system downtime and tool-free nanoViper connections provide fast and reproducible fluidic connections over the complete flow path. For simplified operation and maintenance, new software features enhance performance and usability. As a result, users at various levels of expertise receive an optimized and fully integrated solution designed to consistently generate high quality data. The new Acclaim PepMap nanoLC columns are designed to handle the 1200 bar pressure capability of the EASY-nLC 1200. In particular, the new 75 cm format provides high peak capacity intended to increase sensitivity and resolution. This capability increases the number of protein identifications for improved proteome analysis which delivers excellent confidence in LC-MS results. In combination with the mass spectrometry technologies, the EASY-nLC 1200 pushes the boundaries in proteomics without compromising robustness. This newest addition to nano LC-MS solutions marks an important milestone that brings proteomic laboratories to new levels of biological information.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
TN8:GR €110.46 EUR +0.212

TN8 Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Abbott Laboratories $41.89 USD +0.73
Biogen Inc $269.16 USD -10.72
Danaher Corp $88.51 USD -0.38
Safran SA €71.00 EUR 0.00
Syngenta AG SFr.314.80 CHF -1.30
View Industry Companies

Industry Analysis


Industry Average

Valuation TN8 Industry Range
Price/Earnings 25.7x
Price/Sales 3.0x
Price/Book 2.4x
Price/Cash Flow 25.5x
TEV/Sales 2.1x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact THERMO FISHER SCIENTIFIC INC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at